Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15076 - 15100 of 15136 in total
Investigational
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Experimental
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid
Experimental
Experimental
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Experimental
Doramapimod is a P38 MAP kinase inhibitor.
Investigational
Experimental
Experimental
Experimental
Experimental
Investigational
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Investigational
Displaying drugs 15076 - 15100 of 15136 in total